logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Reports Positive Results From Study On Cancer Drug

Bristol-Myers Squibb Company (BMY) Saturday said an experimental drug showed positive results in patients suffering from melanoma, kidney cancer and lung cancer in a preliminary clinical trial.

Results of the Phase-I study on anti-PD-1 or BMS-936558 in patients with previously-treated non small-cell lung cancer, metastatic melanoma and renal cell carcinoma were encouraging as they showed improvement in patients. The clinical trial added to the understanding of the potential of immuno-oncology as a therapeutic approach in the treatment of cancer, the pharmaceutical firm said.

"Immuno-oncology is a prioritized area of research and development at Bristol-Myers Squibb and we plan to initiate registrational studies for anti-PD-1 in non small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma," Brian Daniels, senior vice president of Global Development and Medical Affairs t Bristol-Myers Squibb, said.

Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Media conglomerate Viacom, Inc. on Tuesday reported a 10 percent decline in profit for the first quarter from last year, reflecting lower revenues in the Filmed Entertainment and Media Networks segments. However, adjusted earnings per share for the quarter matched analysts' expectations, while revenues missed their estimates. Transmission utility ITC Holdings Corp. announced Tuesday that it has entered into an agreement and plan of merger to be acquired by Canadian electric and gas utility company Fortis Inc. in a deal valued at approximately $11.3 billion. ITC shareholders will receive $22.57 in cash and 0.7520 Fortis shares per ITC share. The Coca-Cola Company (KO) reported that its fourth-quarter net income to shareowners increased to $1.24 billion or $0.28 per share from $770 million or $0.17 per share, last year. Adjusted earnings per share was $0.38, for the quarter. On average, 21 analysts polled by Thomson Reuters expected the company...
comments powered by Disqus
RELATED NEWS
Trade BMY now with 
Follow RTT